LONDON, Aug 28 (Reuters) - An experimental Ebola vaccinefrom GlaxoSmithKline is being fast-tracked into humanstudies and the company plans to build up a stockpile of up to10,000 doses for emergency deployment, if results are good.
Britain's biggest drugmaker said on Thursday the researchwas being accelerated with funding from an internationalconsortium, reflecting mounting concern over the worst-everoutbreak of the disease in West Africa that has killed more than1,500 people.
The candidate vaccine, which is being co-developed with theU.S. National Institutes of Health (NIH), is expected to begiven to healthy volunteers in Britain and the United Statesfrom around mid-September, with the programme then beingextended to volunteers in Gambia and Mali. (Reporting by Ben Hirschler, Editing by Paul Sandle)
Glaxosmithkline (GSK)